瑞加诺生
Tier C — Watch / tradeRegadenoson Hydrate
Targets：ADORA2A
Brand：海诺生、Lexiscan、Rapiscan
Indications (approved)：心血管造影剂、诊断剂、造影检查
Regional status
Synthetic routes & intermediates3 routes
Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.
| Code | CAS No. | Intermediate |
|---|---|---|
| REGA-001 | 118-00-3 | 2-amino-9-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1,9-dihydro-6H-purin-6-one |
| REGA-002 | 6979-94-8 | (2R,3R,4R,5R)-2-(acetoxymethyl)-5-(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)tetrahydrofuran-3,4-diyl diacetate |
| REGA-003 | 16321-99-6 | (2R,3R,4R,5R)-2-(acetoxymethyl)-5-(2-amino-6-chloro-9H-purin-9-yl)tetrahydrofuran-3,4-diyl diacetate |
| REGA-004 | 5987-76-8 | (2R,3R,4R,5R)-2-(acetoxymethyl)-5-(6-chloro-2-iodo-9H-purin-9-yl)tetrahydrofuran-3,4-diyl diacetate |
| REGA-005 | 35109-88-7 | (2R,3R,4S,5R)-2-(6-amino-2-iodo-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol |
| REGA-006 | 15763-11-8 | (2R,3R,4S,5R)-2-(6-amino-2-hydrazineyl-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol |
| REGA-007 | 80370-42-9 | ethyl 2-formyl-3-oxopropanoate |
| REGA-008 | 313348-16-2 | ethyl 1-(6-amino-9-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-9H-purin-2-yl)-1H-pyrazole-4-carboxylate |
| Code | CAS No. | Intermediate |
|---|---|---|
| REGA-009 | 37622-90-5 | ethyl 1H-pyrazole-4-carboxylate |
| REGA-010 | 1154383-52-4 | N-methyl-1H-pyrazole-4-carboxamide |
| REGA-011 | 146-78-1 | (2R,3R,4S,5R)-2-(6-amino-2-fluoro-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol |
| Code | CAS No. | Intermediate |
|---|---|---|
| REGA-012 | 5451-40-1 | 2,6-dichloro-9H-purine |
| REGA-013 | 6974-32-9 | (2S,3R,4R,5R)-2-acetoxy-5-((benzoyloxy)methyl)tetrahydrofuran-3,4-diyl dibenzoate |
| REGA-014 | 15373-23-6 | (2R,3R,4R,5R)-2-((benzoyloxy)methyl)-5-(2,6-dichloro-9H-purin-9-yl)tetrahydrofuran-3,4-diyl dibenzoate |
| REGA-015 | 146-77-0 | (2R,3R,4S,5R)-2-(6-amino-2-chloro-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol |
| REGA-016 | 1154383-52-4 | N-methyl-1H-pyrazole-4-carboxamide |
Frequently asked questions
What are the approved indications of Regadenoson Hydrate?
Approved indications include: 心血管造影剂, 诊断剂, 造影检查.
When does the Regadenoson Hydrate patent expire?
No public expiry year is available for Regadenoson Hydrate yet; this page updates once verified.
How many synthesis routes are recorded for Regadenoson Hydrate?
3 synthesis routes are recorded; the shortest is 2 steps with 3 g total yield. Intermediates in each route carry codes and CAS numbers.
Where can I buy Regadenoson Hydrate intermediates?
All intermediates in Regadenoson Hydrate routes have CAS profiles — you can submit an RFQ per CAS and it enters the Unibest matching pool.
How do I get a quote for Regadenoson Hydrate intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-24